We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
Read MoreHide Full Article
Key Takeaways
LXRX shares rose 5.1% after Novo Nordisk began a phase I study of out-licensed oral obesity candidate LX9851.
LX9851 targets ACSL5 and showed added weight loss benefits with Wegovy in preclinical studies.
Lexicon Pharmaceuticals could earn up to $1B in milestones payments plus royalties under its NVO deal.
Shares of Lexicon Pharmaceuticals (LXRX - Free Report) gained 5.1% on Monday after the company announced that its partner, Novo Nordisk (NVO - Free Report) , a dominant player in the obesity market, has initiated an early-stage study of LX9851, a first-in-class, oral non-incretin development candidate.
The phase I study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in 96 people with overweight or obesity. Study completion is expected in the first quarter of 2027.
LX9851 stands out for its novel mechanism of action. It is a potent, selective oral inhibitor of ACSL5, a key enzyme involved in pathways governing fat accumulation and energy balance. It may also trigger the ileal brake mechanism, promoting satiety by slowing gastric emptying and reducing appetite.
In preclinical in vivo studies, LX9851, when used alongside NVO’s blockbuster obesity drug Wegovy (semaglutide), led to greater reductions in body weight, food intake and fat mass compared to Wegovy alone. Additionally, the candidate helped limit weight regain and improved liver steatosis when administered after Wegovy discontinuation.
In early 2025, Lexicon Pharmaceuticals signed an exclusive license agreement with Novo Nordisk, granting the latter an exclusive, worldwide, royalty-bearing right and license to develop, manufacture and commercialize LX9851. LXRX received a $45 million upfront payment and a $10 million milestone payment from NVO as consideration for the agreement.
In the past six months, LXRX shares have gained 22.4% compared with the industry’s 14.4% growth.
Image Source: Zacks Investment Research
Under the agreement, Novo Nordisk will handle all regulatory, development and commercialization activities for LX9851. Lexicon Pharmaceuticals will supply the drug for clinical use at a pre-agreed transfer price for a defined period, after which Novo Nordisk will assume full responsibility for its manufacturing and supply.
Lexicon Pharmaceuticals has received a second $10 million milestone payment from Novo Nordisk in 2026, tied to initial dosing in the phase I study, and could earn an additional $10 million milestone later this year. Overall, LXRX stands to receive up to $1 billion in upfront and potential development, regulatory and sales-based milestones payments, along with tiered royalties on LX9851’s net sales.
Oral obesity therapies are expected to offer a more convenient and potentially lower-cost alternative to once-weekly injectables, reducing treatment burden and broadening patient uptake. Their ease of use may also support better long-term adherence.
Inpefa Anchors LXRX’s Portfolio as Pipeline Progresses
Lexicon Pharmaceuticals’ commercial portfolio has a marketed product, Inpefa (sotagliflozin), which is FDA-approved for heart failure. The company is also currently evaluating sotagliflozin in a pivotal phase III SONATA-HCM study for treating patients with obstructive or nonobstructive hypertrophic cardiomyopathy. Patient enrollment in the study is expected to be completed in mid-2026, with top-line results in the first quarter of 2027.
Lexicon Pharmaceuticals is also evaluating sotagliflozin (Zynquista), despite multiple earlier regulatory setbacks, for its use alongside insulin in adults with type I diabetes (T1D) and chronic kidney disease. Ongoing regulatory proceedings will determine whether approval can be denied. Meanwhile, the FDA has indicated that data from the ongoing third-party-funded, investigator-initiated STENO1 study in Denmark could support a future resubmission. LXRX is targeting a potential new drug application resubmission in 2026, contingent on meeting required safety and patient exposure criteria.
Apart from sotagliflozin, Lexicon Pharmaceuticals’ clinical pipeline also comprises another candidate, pilavapadin (LX9211), which is ready to enter late-stage development for treating diabetic peripheral neuropathic pain.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have risen from $2.55 to $2.87. CPRX shares have gained 21.9% over the past six months.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ADMA Biologics’ 2026 earnings per share (EPS) have increased from 85 cents to 96 cents. ADMA shares have lost 11.3% over the past six months.
ADMA Biologics’ earnings beat estimates in one of the trailing three quarters, matched once and missed on the remaining occasion, with the average negative surprise being 1.79%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
Key Takeaways
Shares of Lexicon Pharmaceuticals (LXRX - Free Report) gained 5.1% on Monday after the company announced that its partner, Novo Nordisk (NVO - Free Report) , a dominant player in the obesity market, has initiated an early-stage study of LX9851, a first-in-class, oral non-incretin development candidate.
The phase I study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in 96 people with overweight or obesity. Study completion is expected in the first quarter of 2027.
LX9851 stands out for its novel mechanism of action. It is a potent, selective oral inhibitor of ACSL5, a key enzyme involved in pathways governing fat accumulation and energy balance. It may also trigger the ileal brake mechanism, promoting satiety by slowing gastric emptying and reducing appetite.
In preclinical in vivo studies, LX9851, when used alongside NVO’s blockbuster obesity drug Wegovy (semaglutide), led to greater reductions in body weight, food intake and fat mass compared to Wegovy alone. Additionally, the candidate helped limit weight regain and improved liver steatosis when administered after Wegovy discontinuation.
In early 2025, Lexicon Pharmaceuticals signed an exclusive license agreement with Novo Nordisk, granting the latter an exclusive, worldwide, royalty-bearing right and license to develop, manufacture and commercialize LX9851. LXRX received a $45 million upfront payment and a $10 million milestone payment from NVO as consideration for the agreement.
In the past six months, LXRX shares have gained 22.4% compared with the industry’s 14.4% growth.
Image Source: Zacks Investment Research
Under the agreement, Novo Nordisk will handle all regulatory, development and commercialization activities for LX9851. Lexicon Pharmaceuticals will supply the drug for clinical use at a pre-agreed transfer price for a defined period, after which Novo Nordisk will assume full responsibility for its manufacturing and supply.
Lexicon Pharmaceuticals has received a second $10 million milestone payment from Novo Nordisk in 2026, tied to initial dosing in the phase I study, and could earn an additional $10 million milestone later this year. Overall, LXRX stands to receive up to $1 billion in upfront and potential development, regulatory and sales-based milestones payments, along with tiered royalties on LX9851’s net sales.
Oral obesity therapies are expected to offer a more convenient and potentially lower-cost alternative to once-weekly injectables, reducing treatment burden and broadening patient uptake. Their ease of use may also support better long-term adherence.
Inpefa Anchors LXRX’s Portfolio as Pipeline Progresses
Lexicon Pharmaceuticals’ commercial portfolio has a marketed product, Inpefa (sotagliflozin), which is FDA-approved for heart failure. The company is also currently evaluating sotagliflozin in a pivotal phase III SONATA-HCM study for treating patients with obstructive or nonobstructive hypertrophic cardiomyopathy. Patient enrollment in the study is expected to be completed in mid-2026, with top-line results in the first quarter of 2027.
Lexicon Pharmaceuticals is also evaluating sotagliflozin (Zynquista), despite multiple earlier regulatory setbacks, for its use alongside insulin in adults with type I diabetes (T1D) and chronic kidney disease. Ongoing regulatory proceedings will determine whether approval can be denied. Meanwhile, the FDA has indicated that data from the ongoing third-party-funded, investigator-initiated STENO1 study in Denmark could support a future resubmission. LXRX is targeting a potential new drug application resubmission in 2026, contingent on meeting required safety and patient exposure criteria.
Apart from sotagliflozin, Lexicon Pharmaceuticals’ clinical pipeline also comprises another candidate, pilavapadin (LX9211), which is ready to enter late-stage development for treating diabetic peripheral neuropathic pain.
Lexicon Pharmaceuticals, Inc. Price and Consensus
Lexicon Pharmaceuticals, Inc. price-consensus-chart | Lexicon Pharmaceuticals, Inc. Quote
LXRX’s Zacks Rank & Stocks to Consider
Lexicon Pharmaceuticals currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and ADMA Biologics (ADMA - Free Report) . While CPRX sports a Zacks Rank #1 (Strong Buy), ADMA carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have risen from $2.55 to $2.87. CPRX shares have gained 21.9% over the past six months.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ADMA Biologics’ 2026 earnings per share (EPS) have increased from 85 cents to 96 cents. ADMA shares have lost 11.3% over the past six months.
ADMA Biologics’ earnings beat estimates in one of the trailing three quarters, matched once and missed on the remaining occasion, with the average negative surprise being 1.79%.